Sangamo Therapeutics, Inc. announced that R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations will be leaving the company on July 10, 2023. Phillip Ramsey, currently serving as Vice President, Technical Development, has been appointed as Head of Technical Operations effective May 29, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6496 USD | +6.72% | +15.71% | +19.57% |
May. 09 | Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.57% | 135M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Announces Executive Changes